DURHAM — Scion NeuroStim, Inc. has recently filed with the SEC to disclose nearly $10 million in equity funding. The biotechnology company’s filing involved 13 investors and brought in a total of $9,999,978. This is the company’s first filing.

According to the company website, Scion NeuroStim is “committed to improving the lives of patients suffering from diseases and disorders of the central nervous system through the development of innovative and easy-to-use, non-invasive neuromodulation medical devices.” The website lists 21 patents and states that other patents are pending in the U.S. and internationally. The site also mentions that the FDA has not conveyed marketing authorization for its products, and they are not available for sale.

Medical devices must ‘monitor, identify, address’ cybersecurity threats, FDA rules

Scion NeuroStim, LLC was formed in North Carolina in 2007 but was converted to a business corporation in January of last year. Both the company and the SEC filing list Lanty Smith and Steven Bischoff as directors. Lesco Rogers, also a “director” in the SEC filing is the company’s Chief Medical Officer, according to LinkedIn. LinkedIn lists Rober Black, who signed the SEC filing, as the company’s CTO and COO.